Clinical features and genetics of progressive myoclonus epilepsy of the Unverricht-Lundborg type

Annals of Medicine

Volumn 30, Issue 5, 1998, Pages 474-480

  Lehesjoki, Anna Elina ^a   Koskiniemi, Marjaleena ^b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Cystatin B; Disease gene; EPM1; Mutation; Progressive myoclonus epilepsy; Unverricht Lundborg disease

Indexed keywords

ANTICONVULSIVE AGENT; CYSTATIN; CYSTEINE PROTEINASE INHIBITOR;

ARTICLE; CLINICAL FEATURE; DISEASE COURSE; ELECTROENCEPHALOGRAPHY; GENE MAPPING; GENE MUTATION; HUMAN; MOLECULAR CLONING; MOLECULAR GENETICS; MYOCLONUS EPILEPSY; ONSET AGE; PHOTOSENSITIVITY; PHOTOSTIMULATION; PRIORITY JOURNAL; PROMOTER REGION; TONIC CLONIC SEIZURE;

EID: 0031727374     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.3109/07853899809002489     Document Type: Article

References (61)

1. Berkovic SF, Andermann F, Carpenter S, Wolfe L. Progressive myoclonus epilepsies: specific causes and diagnosis. N Engl J Med 1986; 31: 296-304.
2. Roger J, Genton P, Bureau M, Dravet C. Progressive myoclonus epilepsies in childhood and adolescence. In: Roger J, Bureau M, Dravet C, Dreifuss FE, Perret A, Wolf P, eds. Epileptic Syndromes in Infancy, Childhood and Adolescence. 2nd edn. London: John Libbey; 1992: 381-400.
3. Marseille Consensus Group. Classification of progressive myoclonus epilepsies and related disorders. Ann Neurol 1990; 28: 113-6.
4. Unverricht H. Die Myoclonie. Leipzig: Franz Deuticke; 1891.
5. Lundborg H. Die progressive Myoklonus Epilepsie (Unverricht's Myoclonie). Uppsala, Sweden: Almquist and Wiksell; 1903.
6. Lafora GR. Über das vorkommen amyloider Körperchen im innern der Ganglienzellen; zugleich ein zum Studium der amyloiden Substanz im Nervensystem. Virchows Arch Path Anat 1911; 205: 295-303.
7. Haltia M, Kristensson K, Sourander P. Neuropathological studies in three Scandinavian cases of progressive myoclonus epilepsy. Acta Neurol Scand 1969; 45: 63-77.
8. Koskiniemi M, Donner M, Majuri H, Haltia M, Norio R. Progressive myoclonus epilepsy: a clinical and histopathologic study. Acta Neurol Scand 1974; 50: 307-32.
9. Koskiniemi M, Toivakka E, Donner M. Progressive myoclonus epilepsy. Electroencephalographical findings. Acta Neurol Scand 1974; 30: 33-359.
10. Koskiniemi M. Psychological findings in progressive myoclonus epilepsy without Lafora bodies. Epilepsia 1974; 15: 537-45.
11. Norio R, Koskiniemi M. Progressive myoclonus epilepsy: genetic and nosological aspects with special reference to 107 Finnish patients. Clin Genet 1979; 15: 382-98.
12. Eldridge R, Iivanainen M, Stern R, Koerber T, Wilder BJ. "Baltic" myoclonus epilepsy: hereditary disorder of childhood made worse by phenytoin. Lancet 1983; 2: 838-42.
13. Genton P, Michelucci R, Tassinari CA, Roger J. The Ramsay Hunt syndrome revisited: Mediterranean myoclonus versus mitochondrial encephalomyopathy with ragged-red fibers and Baltic myoclonus. Acta Neurol Scand 1990; 81: 8-15.
14. Koskiniemi M. Baltic myoclonus. Adv Neurol 1986: 43: 57-64.
15. Koskiniemi M. Baltic myoclonus. Ann Clin Res 1987; 19: 311-12.
16. Kyllerman M, Sommerfelt TK, Hedström A, Wennergren G, Holmgren D. Clinical and neurophysiological development of Unverricht-Lundborg disease in four Swedish siblings. Epilepsia 1991; 32: 900-9.
17. Koskiniemi M. Findings in routine laboratory examination in progressive myoclonus epilepsy. Acta Neural Scand 1975; 51: 12-20.
18. Koskiniemi M, Palo J. Urinary excretion of indican in progressive myoclonus epilepsy without Lafora bodies: the effect of sodium valproate. J Neurol Sci 1978; 39: 235-9.
19. Chadwick, D, Jenner P, Reynolds EH. Serotonin metabolism in human epilepsy: the influence of anticonvulsant drugs. Ann Neurol 1977; 1: 218-24.
20. Leino E, MacDonald E, Airaksinen M, Riekkinen PJ. Homovanillic acid and 5-hydroxyindoleacetic acid levels in cerebrospinal fluid of patients with progressive myoclonus epilepsy. Acta Neurol Scand 1980; 62: 41-54.
21. Koskiniemi M, Laakso J, Härkönen M, Laipio M, Kuurne T. Indole levels in human lumbar and ventricular cerebrospinal fluid and the effect of L-tryptophan administration. Acta Neurol Scand 1985; 71: 127-37.
22. Hari R, Salmi T, Bergström L, Murros K. Brainstem and auditory evoked potentials in progressive myoclonus epilepsy without Lafora bodies. Acta Neurol Scand 1983; 67: 376-8.
23. Shibasaki H, Yamashita Y, Neshige R, Tobimatsu S, Fukui R. Pathogenesis of giant somatosensory evoked potential in progressive myoclonus epilepsy. Brain 1985; 108: 225-40.
24. Mervaala E, Keränen T, Pääkkönen A, Partanen J, Riekkinen P. Visual evoked potentials, brainstem auditory evoked potentials and quantitative EEG in Baltic progressive myoclonus epilepsy. Epilepsia 1986; 27: 542-7.
25. Reutens DC, Puce A, Berkovic SF. Cortical hyperexcitability in progressive myoclonus epilepsy. Neurology 1993; 43: 186-92.
26. Karhu J, Hari R, Paetau R, Kajola M, Mervaala E. Cortical reactivity in progressive myoclonus epilepsy. Electroencephalogr Clin Neurophysiol 1994; 90: 93-102.
27. Cochius J, Carpenter S, Andermann E, et al. Sweat gland vacuoles in Unverricht-Lundborg disease: a clue to diagnosis? Neurology 1994; 44: 2372-5.
28. Harenko A, Toivakka E. Myoclonus epilepsy (Unverricht-Lundborg) in Finland. Acta Neurol Scand 1961; 37: 282-96.
29. Iivanainen M, Himberg JJ. Valproate and clonazepam in the treatment of severe progressive myoclonus epilepsy. Arch Neurol 1982; 39: 236-8.
30. Soinerville ER, Olanow W. Valproic acid. Treatment of myoclonus in dyssynergia cerebellaris myoclonica. Arch Neurol 1982; 39: 527-8.
31. Goldberg MA, Dorman JD. Intention myoclonus: successful treatment with clonazepam. Neurology 1976; 26: 24-6.
32. Chadwick D, Hallett M, Harris R, Jenner P, Reynolds EH, Marsden CD. Clinical biochemical and physiological features distinguishing myoclonus responsive to 5-hydroxytryptophan, tryptophan with a monoamine oxidase inhibitor, and clonazepam. Brain 1977; 100: 455-87.
33. Koskiniemi M, Hyyppä M, Sainio K, Salmi T, Sarna S, Uotila L. Transient effect of L-tryptophan in progressive myoclonus epilepsy without Lafora bodies: clinical and electrophysiological study. Epilepsia 1980; 21: 351-7.
34. Pranzatelli MR, Tate E, Huang Y, et al. Neuropharmacology of progressive myoclonus epilepsy: response to 5-hydroxy-L-tryptophan. Epilepsia 1995; 36: 783-91.
35. Remy C, Genton P. Effect of high dose of oral piracetam on myoclonus in progressive myoclonus epilepsy (Mediterranean myoclonus). Epilepsia 1991; 32: 6.
36. Gouliaev AH, Senning A. Piracetam and other structurally related nootropics. Brain Res Rev 1994; 19: 180-222.
37. Koskiniemi M, Van Vleymen B, Hakamies L, Lamusuo S, Taalas J. Piracetam relieves symptoms in progressive myoclonus epilepsy: a multicentre, randomised, double blind, crossover study comparing the efficacy and safety of three dosages of oral piracetam with placebo. J Neurol Neurosurg Psychiatry 1998; 64: 344-8.
38. Lehesjoki A-E, Koskiniemi M, Sistonen P, et al. Localization of a gene for progressive myoclonus epilepsy to chromosome 21q22. Proc Natl Acad Sci USA 1991; 88: 3696-9.
39. Lehesjoki A-E, Koskiniemi M, Pandolfo M, et al. Linkage studies in progressive myoclonus epilepsy: Unverricht-Lundborg and Lafora diseases. Neurology 1992; 42: 1545-50.
40. Lehesjoki A-E, Koskiniemi M, Norio R, et al. Localization of the EPM1 gene for progressive myoclonus epilepsy on chromosome 21: linkage disequilibrium allows high resolution mapping. Hum Mol Genet 1993; 2: 1229-34.
41. Lehesjoki A-E, Eldridge R, Eldridge J, Wilder BJ, de la Chapelle A. Progressive myoclonus epilepsy of Unverricht-Lundborg type: a clinical and molecular genetic study of a family from the United States with four affected sibs. Neurology 1993; 43: 2384-6.
42. de la Chapelle A. Disease gene mapping in isolated human populations: the example of Finland. J Med Genet 1993; 30: 857-65.
43. Virtaneva K, Miao J, Träskelin, et al. Progressive myoclonus epilepsy EPM1 locus maps to a 175 kb interval in distal 21q. Am J Hum Genet 1996; 58: 1247-53.
44. Stone NE, Fan J-B, Willour V, et al. Construction of a 750 kb bacterial clone contig and restriction map in the region of human chromosome 21 containing the progressive myoclonus epilepsy (EPM1) gene. Genome Res 1996; 6: 218-25.
45. Pennacchio LA, Lehesjoki A-E, Stone NE, et al. Mutations in the gene encoding cystatin B in progressive myoclonus epilepsy (EPM1). Science 1996; 271: 1731-4.
46. Järvinen M, Rinne A. Human spleen cysteineprotease inhibitor. Purification, fractionation into isoelectric variants and some properties of the variants. Biochim Biophys Acta 1982; 708: 210-17.
47. Turk V, Bode W. The cystatins: protein inhibitors of cysteine proteinases. FEBS Lett 1991; 285: 213-9.
48. Jerala R, Trstenjak M, Lenarcic, Turk V. Cloning a synthetic gene for human stefin B and its expression in E. coli. FEBS Lett 1988; 239: 41-4.
49. Ritonja A, Machleidt W, Barrett AJ. Amino acid sequence of the intracellular cysteine proteinase inhibitor cystatin B from human liver. Biochem Biophys Res Commun 1985; 131: 1187-92.
50. Lalioti MD, Mirotsou M, Buresi C, et al. Identification of mutations in cystatin B, the gene responsible for the Unverricht-Lundborg type of progressive myoclonus epilepsy (EPM1). Am J Hum Genet 1997; 60: 342-51.
51. Lafreniere RG, Rochefort DL, Chretien N, et al. Unstable insertion in the 5′-flanking region of the cystatin-B gene is the most common mutation in progressive myoclonus epilepsy type-1, EPM1. Nat Genet 1997; 15: 298-302.
52. Virtaneva K, D'Amato E, Miao J, et al. Unstable minisatellite expansion causing recessively inherited myoclonus epilepsy, EPM1. Nat Genet 1997; 15: 393-6.
53. Lalioti MD, Scott HS, Buresi C, et al. Dodecamer repeat expansion in cystatin B gene in progressive myoclonus epilepsy. Nature 1997; 386: 847-51.
54. Lalioti MD, Scott HS, Antonarakis SE. What is expanded in progressive myoclonus epilepsy? Nat Genet 1997; 17: 17.
55. Virtaneva K, Paulin L, Krahe R, de la Chapelle A, Lehesjoki A-E. The minisatellite expansion mutation in EPM1: resolution of an initial discrepancy. Hum Mutat 1998; 12: 218.
56. Warren ST. The expanding world of trinucleotide repeats. Science 1996; 271: 1374-5.
57. Lalioti MD, Scott HS, Genton P, et al. A PCR amplification method reveals instability of the dodecamer repeat in progressive myoclonus epilepsy (EPM1) and no correlation between the size of the repeat and age at onset. Am J Hum Genet 1998; 62: 842-47.
58. Roger J, Soulayrol R, Hassoun J. La dyssynergie cerebelleuse myoclonique (syndrome de Ramsay Hunt). Rev Neurol 1968; 119: 85-106.
59. Tassinari CA, Michelucci R, Genton P, Pellissier JF, Roger J. Dyssynergia cerebellaris myoclonica (Ramsay Hunt syndrome): a condition unrelated to mitochondrial encephalomyopathies. J Neurol Neurosurg Psychiatry 1989; 52: 262-5.
60. Malafosse A, Lehesjoki A-E, Genton P, Laubauge P. Identical genetic locus for Baltic and Mediterranean myoclonus. Lancet 1992; 339: 1080-1.
61. Lehesjoki A-E, Tassinari CA, Avanzini G, et al. PME of Unverricht-Lundborg type in the Mediterranean region: linkage and linkage disequilibrium confirm the assignment to the EPM1 locus. Hum Genet 1994; 93: 668-74.